Trial exclusion patterns Phase 2 and Phase 3 retatrutide trials commonly excluded participants with a history of pancreatitis, medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), severe gastroparesis, recent major cardiovascular events, severe kidney impairment, type 1 diabetes (in the obesity studies), and pregnancy or breastfeeding
Clinicians often advise stopping at about 75% of what feels like "full." Prioritize protein 2530 grams at each meal, aiming for at least 1.01.2 g per kg of body weight daily
Gala describes a nationwide pharmacy network across 50 states
Weekly during an initial loading phase (46 weeks), then every 12 weeks for maintenance
Semaglutide GLP-1 has been shown to reduce visceral adipose tissue, or belly fat, in patients with obesity
Semaglutide trials reported 24-29% constipation rates while tirzepatide trials showed 12-27%